While Akt inhibitors such as MK-2206 and capivasertib (AZD5363) have shown moderate anti-tumor activities in cancers including prostate cancer, melanoma, and breast cancer, their clinical efficacy has often been limited, especially when they are used as monotherapy or when they are combined with chemotherapy.33 The gene discussed is AKT1; the disease is prostate carcinoma.